Shan et al., 2012 - Google Patents
Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem studyShan et al., 2012
View PDF- Document ID
- 3174835150812571207
- Author
- Shan L
- Bossers K
- Luchetti S
- Balesar R
- Lethbridge N
- Chazot P
- Bao A
- Swaab D
- Publication year
- Publication venue
- Neurobiology of aging
External Links
Snippet
Earlier studies showed neuronal histamine production in the hypothalamic tuberomamillary nucleus to be unchanged in Parkinson's disease (PD), whereas the histamine levels and innervation in the substantia nigra (SN) increased. In the present study we used quantitative …
- 210000003523 Substantia Nigra 0 title abstract description 103
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shan et al. | Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study | |
| Hall et al. | Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease | |
| JP5823964B2 (en) | Methods for diagnosing and treating autism | |
| BRPI0718413A2 (en) | METHODS FOR PREDICTING SENSITIVITY OF A CONCEROUS CELL TO A FIRST ANTICCAN AGENT, TO PREDICT OR MONITOR EFFECTIVENESS OF AN ANTICAN AGENT, AND TO DETERMINE AN EFFECTIVE DOSE FOR ANTICCAN AGENT, DETECTION KIT, AND AXIS, A SYSTEM OF DETECTION | |
| Datta et al. | Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers | |
| US6884591B2 (en) | Peripheral marker of blood brain barrier permeability | |
| KR101873499B1 (en) | A biomarker for diagnosing vascular diseases and the uses thereof | |
| JP5701994B2 (en) | Citrullinated proteins: post-translational modification of myocardial proteins as markers of physiological and pathological diseases | |
| Lei et al. | Protein O-GlcNAcylation coupled to Hippo signaling drives vascular dysfunction in diabetic retinopathy | |
| US20200138951A1 (en) | Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction | |
| WO2018183213A1 (en) | Blood biomarkers and diagnostic methods for small vessel diseases | |
| Zhang et al. | Spermidine mediates acetylhypusination of RIPK1 to suppress diabetes onset and progression | |
| Hodes et al. | Na+, K+-ATPase α3 isoform in frontal cortex GABAergic neurons in psychiatric diseases | |
| Yuan et al. | Analysis of the clinical diagnostic value of GMFB in cerebral infarction | |
| Wang et al. | Coexpression of MAST205 inhibits the activity of Na+/H+ exchanger NHE3 | |
| Güzel et al. | Cerebrospinal fluid of preeclamptic and normotensive pregnant women compared to nonpregnant women analyzed with mass spectrometry | |
| US20230144446A1 (en) | Blood-based diagnostic assays for alzheimer's disease | |
| Cao et al. | Reactivation of Mthfd2 during heart failure drives cardiac remodeling | |
| Chai et al. | A novel Transcript is Up‐Regulated by Fasting in the Hypothalamus and Enhances Insulin Signalling | |
| Delaidelli et al. | α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant | |
| CN117795340A (en) | Biomarkers and their uses | |
| Hindges et al. | MyosinV controls PTEN function and neuronal cell size | |
| Escher | Proteomic profiling of Duchenne muscular dystrophy: Protein patterns and candidate markers of disease | |
| HK1171080A (en) | Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction | |
| JP2011215091A (en) | Method for screening substance inhibiting c-met enzyme activity |